SCHEMBL904599

SCHEMBL904599

CCc1cc(Br)ccc1S(=O)(=O)NCc1ccc2c(cnn2C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
KMT2A Q03164 8/20 0.39
ALDH1A1 P00352 7/20 0.39
MEN1 O00255 7/20 0.39
MAPT P10636 6/20 0.39
THRB P10828 4/20 0.39
RECQL P46063 4/20 0.39
SLC6A9 P48067 1/20 0.39
PKM P14618 1/20 0.39
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
S100A4 P26447 1/20 0.38
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
CTNNB1 P35222 1/20 0.37
TCF7 P36402 1/20 0.37
FGB P02675 1/20 0.36
PABPC1 P11940 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL904735 0.88 CA1 (0.46) LMNAKMT2AALDH1A1MEN1MAPT
SCHEMBL904754 0.87 CA1 (0.42) LMNAKMT2AALDH1A1MEN1MAPT
SCHEMBL904760 0.83 POLB (0.41) KMT2AALDH1A1MEN1MAPTTHRB
SCHEMBL25213780 0.75 ALDH1A1 (0.68) LMNAKMT2AALDH1A1MEN1MAPT
SCHEMBL25220708 0.74 ALDH1A1 (0.56) LMNAKMT2AALDH1A1MEN1MAPT
SCHEMBL904700 0.74 CA1 (0.42) LMNAKMT2AALDH1A1MEN1MAPT
SCHEMBL16568639 0.74 LMNA (0.68) LMNAKMT2AALDH1A1MAPTPKM
SCHEMBL904733 0.73 PDE1C (0.43) KMT2AALDH1A1MEN1MAPTTHRB
SCHEMBL904717 0.73 MAOA (0.43) LMNAALDH1A1MAPTTHRBRECQL
SCHEMBL904680 0.70 CA1 (0.47) LMNAKMT2AALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829026-B2 Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2014-09-09 US disclosed
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2013-08-15 US disclosed
WO-2012042915-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210858-A1 SULFAMOYL BENZOIC ACID HETEROBICYCLIC DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM6, TRPM5 LMNA 3275/4885KMT2A 1391/4885ALDH1A1 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.